TABLE 3.
Prehospitalization Medication Use and In-Hospital Treatments Among U.S. Asian Patients With Any HF, Stratified According to Sex
| Asian Indian | Chinese | Filipino/Filipina | Japanese | Korean | Vietnamese | Other Asian | NHW | |
|---|---|---|---|---|---|---|---|---|
| Male | ||||||||
| N | 677 | 525 | 933 | 350 | 176 | 304 | 1,017 | 409,762 |
| Prehospitalization medication use | ||||||||
| ACE inhibitor, ARB, or ARNI | 215 (51) | 151 (44) | 264 (42) | 92 (40) | 70 (52) | 110 (46) | 363 (48) | 65,122 (40) |
| Beta-blocker | 306 (72) | 220 (64) | 424 (67) | 143 (62) | 84 (62) | 147 (61) | 476 (63) | 103,465 (64) |
| MRA | 41 (10) | 33 (10) | 49 (8) | 17 (7) | 16 (12) | 22 (9) | 99 (13) | 24,599 (15) |
| In-hospital treatments | ||||||||
| No procedure | 256 (64) | 267 (77) | 412 (66) | 153 (77) | 81 (58) | 165 (67) | 506 (64) | 162,808 (72) |
| Coronary interventiona | 20 (5) | 4 (1) | 9 (1) | 3 (2) | 5 (4) | 3 (1) | 22 (3) | 5,319 (2) |
| Valve interventionb | 2 (1) | 2 (1) | 1 (0.2) | 1 (1) | 1 (1) | 1 (0.4) | 6 (1) | 1,019 (1) |
| Renal replacement therapyc | 32 (8) | 19 (6) | 81 (13) | 15 (8) | 19 (14) | 31 (13) | 101 (13) | 11,098 (5) |
| Rhythm deviced | 12 (3) | 2 (1) | 8 (1) | 1 (1) | 3 (2) | 5 (2) | 18 (2) | 5,684 (3) |
| Female | ||||||||
| N | 466 | 436 | 665 | 348 | 184 | 261 | 919 | 358,804 |
| Prehospitalization medication use | ||||||||
| ACE inhibitor, ARB, or ARNI | 111 (41) | 127 (45) | 196 (44) | 87 (41) | 56 (44) | 87 (41) | 300 (44) | 53,210 (38) |
| Beta-blocker | 197 (72) | 175 (62) | 322 (72) | 127 (60) | 70 (56) | 128 (60) | 451 (66) | 89,498 (64) |
| MRA | 18 (7) | 31 (11) | 12 (3) | 10 (5) | 10 (8) | 20 (9) | 54 (8) | 17,745 (13) |
| In-hospital treatments | ||||||||
| No procedure | 179 (69) | 206 (75) | 329 (70) | 171 (82) | 100 (70) | 147 (69) | 507 (69) | 154,018 (78) |
| Coronary interventiona | 3 (1) | 2 (1) | 4 (1) | 1 (1) | 2 (1) | 4 (2) | 15 (2) | 2,839 (1) |
| Valve interventionb | 1 (0.4) | 1 (0.4) | 1 (0.2) | 0 (0) | 0 (0) | 1 (1) | 2 (0.3) | 638 (0.3) |
| Renal replacement therapyc | 23 (9) | 14 (5) | 61 (13) | 10 (5) | 14 (10) | 35 (16) | 92 (13) | 7,717 (4) |
| Rhythm deviced | 4 (2) | 5 (2) | 3 (1) | 4 (2) | 2 (1) | 3 (1) | 13 (2) | 3,041 (2) |
Values are N or n (%). Frequencies and percentages are among patients with any ejection fraction, with denominators excluding patients with missing data for each metric.
Includes PCI, PCI with stent, or CABG.
Includes transcatheter mitral valve replacement, tricuspid valve procedure, cardiac valve surgery, or transcatheter aortic valve replacement.
Includes ultrafiltration, dialysis or ultrafiltration unspecified, or dialysis.
Rhythm device includes cardiac resynchronization therapy-pacing only, implantable cardioverter-defibrillator, pacemaker, or cardiac resynchronization therapy with implantable cardioverter-defibrillator.
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; MRA = mineralocorticoid receptor antagonist; other abbreviations as in Table 1.